Tag: NIH
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Featured Article
AVEVA and Schneider Electric spearhead digital transformation in mining
AVEVA, a global leader in industrial software driving digital transformation, has partnered with Schneider Electric to redefine what smart, sustainable mining looks like in the age of AI.
